Janux Therapeutics, Inc. JANX
Janux Therapeutics, Inc. (Nasdaq: JANX) is an oncology drug developer. Its lead program, JANX007, is in Phase 1 for metastatic castration-resistant prostate cancer (PSMA). Its next catalyst on record is JANX013: Enter clinical development (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: JANX013 — Enter clinical development (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| JANX007 | mCRPC | antibody | Phase 1 |
| JANX008 | EGFR solid tumors | antibody | Phase 1 |
| JANX014 | PSMA-targeted TRACTr (mCRPC) | antibody | Phase 1 |
| JANX011 | CD19-ARM, healthy volunteers | antibody | Phase 1 |
| JANX013 | PSMA TRACIr | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.